Alto Neuroscience has raised $100 million through an underwritten registered [...]

Compass Pathways has reported positive six-month results from its second [...]

Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

Researchers have identified a molecular target that could extend the [...]

Compass Pathways has reported that its second pivotal Phase 3 [...]

FundaMental Pharma GmbH will present new preclinical data on its [...]

Alto Neuroscience has strengthened its intellectual property position around its [...]

New approach targets Elk1 to restore neuroplasticity without sedation or [...]